Cargando…

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer

Detalles Bibliográficos
Autores principales:	Bansal, GJ, Santosh, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601839/ http://dx.doi.org/10.1186/1470-7330-15-S1-P18

Ejemplares similares

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer compared to other subtypes of breast cancer
por: Bansal, Gaurav J, et al.
Publicado: (2016)

An immune surveillance model to monitor the response to neo-adjuvant chemotherapy treatment in breast cancer patients
por: Bernal-Estévez, David A, et al.
Publicado: (2015)

The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
por: Hiller, Louise, et al.
Publicado: (2013)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

The role of magnetic resonance imaging (MRI) in invasive lobular breast cancer based on mammographic density
por: Bansal, GJ, et al.
Publicado: (2015)

Study of circulating myeloid derived suppressor cells (MDSC) in patients with breast cancer undergoing neo-adjuvant chemotherapy; interim results
por: Wesolowski, Robert, et al.
Publicado: (2013)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
por: Tang, Yiqing, et al.
Publicado: (2012)

To assess the clinical usefulness of radio-opaque marker insertion into malignant breast tumours in patients undergoing neo-adjuvant chemotherapy prior to consideration of breast-conserving surgery
por: Evans, SE, et al.
Publicado: (2006)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

PB.03: Evaluating the role of breast MRI at mid-cycle chemotherapy
por: Santosh, D, et al.
Publicado: (2013)

[(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
por: Raccagni, Isabella, et al.
Publicado: (2018)

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
por: Gámez-Pozo, Angelo, et al.
Publicado: (2017)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer
por: Chintamani, et al.
Publicado: (2007)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

Screen-detected breast cancer: does presence of minimal signs on previous mammograms predict staging/grading of cancer?
por: Bansal, GJ, et al.
Publicado: (2009)

Use of MRI to predict response following neoadjuvant chemotherapy for breast cancer: how accurately can it guide surgical choice?
por: Tan, Sue, et al.
Publicado: (2015)

Correlation of post-neoadjuvant chemotherapy response on MRI with final histology in breast cancer patients
por: Mahatma, Anjum, et al.
Publicado: (2015)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
por: Madeira, Klesia, et al.
Publicado: (2014)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
por: Assadipour, Yasmine, et al.
Publicado: (2015)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy
por: Koppiker, Chaitanyanand B., et al.
Publicado: (2023)

Changes in leukoencephalopathy and serum neurofilament after (neo)adjuvant chemotherapy for breast cancer
por: Schroyen, Gwen, et al.
Publicado: (2023)

Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? -A prospective clinical study
por: Chintamani, et al.
Publicado: (2004)

Phenotypic analysis of breast cell lines – triple negative cells vs expressing hormonal receptors
por: Laranjo, Mafalda, et al.
Publicado: (2010)

Integrating GWAS with gene expression data to dissect the genetic architecture of triple-negative breast cancer
por: Hicks, Chindo, et al.
Publicado: (2011)

An integrative genomics approach for mapping the emerging genetic susceptibility landscape of triple-negative breast cancer
por: Hicks, Chindo, et al.
Publicado: (2012)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

PB.24: Is digital breast tomosynthesis helpful within a symptomatic one-stop breast clinic for characterisation of subtle findings?
por: Bansal, GJ, et al.
Publicado: (2013)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
por: Absmaier, Magdalena, et al.
Publicado: (2018)

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
por: Horimoto, Y, et al.
Publicado: (2015)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_brl2d21oebvkjbnm1mlg0pion1